Review: Dipeptidyl peptidase-4 inhibitors do not increase overall adverse events in type 2 diabetes

被引：2
作者：
Chatterjee, Saurav [1 ,2 ]
Chatterjee, Sanjay [3 ]
机构：
[1] Brown Univ, Providence, RI 02912 USA
[2] Providence VAMC, Providence, RI USA
[3] Apollo Gleneagles Hosp, Kolkata, W Bengal, India
来源：
ANNALS OF INTERNAL MEDICINE | 2013年 / 158卷 / 08期
关键词：
METAANALYSIS;
D O I：
10.7326/0003-4819-158-8-201304160-02008
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
[41]   Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials [J].
Wang, Na ;
Yang, Tao ;
Li, Jie ;
Zhang, Xianfeng .
DIABETES METABOLIC SYNDROME AND OBESITY, 2019, 12 :1513-1526
[42]   Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysis [J].
Kim, Yeong Gi ;
Min, Se Hee ;
Hahn, Seokyung ;
Oh, Tae Jung ;
Park, Kyong Soo ;
Cho, Young Min .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 116 :86-95
[43]   Effect of Dipeptidyl Peptidase-4 Inhibitors on the Risk of Bone Fractures in a Korean Population [J].
Ustulin, Morena ;
Park, So Young ;
Choi, Hangseok ;
Chon, Suk ;
Woo, Jeong-Taek ;
Rhee, Sang Youl .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2019, 34 (35)
[44]   Use of dipeptidyl peptidase-4 inhibitors is associated with a lower risk of rheumatoid arthritis in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of cohort studies [J].
Charoenngam, Nipith ;
Rittiphairoj, Thanitsara ;
Ponvilawan, Ben ;
Ungprasert, Patompong .
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (01) :249-255
[45]   Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice [J].
Kanda, Junkichi ;
Furukawa, Megumi ;
Izumo, Nobuo ;
Shimakura, Taketoshi ;
Yamamoto, Noriaki ;
Takahashi, Hideaki E. ;
Wakabayashi, Hiroyuki .
DRUG DISCOVERIES AND THERAPEUTICS, 2020, 14 (05) :218-225
[46]   Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis [J].
Wu, D. ;
Li, L. ;
Liu, C. .
DIABETES OBESITY & METABOLISM, 2014, 16 (01) :30-37
[47]   Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis [J].
Dutta, Deep ;
Agarwal, Anshita ;
Maisnam, Indira ;
Singla, Rajiv ;
Khandelwal, Deepak ;
Sharma, Meha .
ENDOCRINOLOGY AND METABOLISM, 2021, 36 (02) :374-387
[48]   Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System [J].
Raschi, E. ;
Poluzzi, E. ;
Koci, A. ;
Antonazzo, I. C. ;
Marchesini, G. ;
De Ponti, F. .
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2016, 26 (05) :380-386
[49]   Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials [J].
Monami, M. ;
Iacomelli, I. ;
Marchionni, N. ;
Mannucci, E. .
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2010, 20 (04) :224-235
[50]   The Assessment of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Glucocorticoid-induced Diabetes by Continuous Glucose Monitoring [J].
Yata, Yusuke ;
Hosojima, Michihiro ;
Kabasawa, Hideyuki ;
Ishikawa, Tomomi ;
Kaseda, Ryohei ;
Iino, Noriaki ;
Suzuki, Yoshiki ;
Saito, Akihiko ;
Narita, Ichiei .
INTERNAL MEDICINE, 2017, 56 (19) :2555-2562
12345